Treatment for melanoma depends heavily on stage, which is determined by how deeply the tumor has grown and whether it has spread to lymph nodes or other organs.
Early-stage melanoma (Stage 0 and Stage I) is often cured with surgery alone, and survival rates are excellent.
Stage III and IV melanoma now have highly effective systemic therapies, including checkpoint inhibitor immunotherapy and BRAF-targeted drugs, that have transformed outcomes over the past decade.
BRAF mutation testing is standard after diagnosis because it opens the door to targeted therapy options.
Side effects from immunotherapy can mimic autoimmune conditions and require prompt attention from your care team.
Doctronic.ai connects you with clinicians who can answer follow-up questions about your melanoma treatment plan between appointments.
A melanoma diagnosis does not immediately tell you which treatment you need. That answer comes from staging, a process that determines how far the cancer has advanced.
Two measurements matter most for thin tumors: Breslow depth (how many millimeters the melanoma extends into the skin) and, in some cases, Clark level (which skin layer it has reached). Tumors thicker than 0.8 millimeters, or thinner ones with certain high-risk features like ulceration or a high mitotic rate, typically prompt a sentinel lymph node biopsy.
A sentinel lymph node biopsy removes the first lymph node or nodes to which a tumor drains. If cancer cells are present there, the stage moves up and treatment options change significantly. If the nodes are clear, the prognosis improves considerably.
Staging runs from Stage 0 (melanoma in situ, confined to the top layer of skin) through Stage IV (spread to distant organs). Understanding where you land on that spectrum is the foundation of every melanoma treatment decision that follows.
For melanoma caught at its earliest stages, the primary treatment is wide local excision. A surgeon removes the tumor along with a margin of surrounding healthy skin, the size of which is guided by Breslow depth. This outpatient procedure is typically performed under local anesthesia.
For Stage 0 (melanoma in situ), a 0.5 to 1 cm margin is usually sufficient. For Stage I tumors, margins of 1 cm are standard for thinner lesions, widening to 1 to 2 cm for thicker ones.
At this stage, the cure rate is very high. After surgery, the main priority shifts to close monitoring: regular full-body skin exams every three to twelve months and awareness of any new or changing spots.
Stage II melanoma is still confined to the original tumor site but is thicker, ulcerated, or has other features that raise the risk of recurrence. Wide local excision remains the core treatment, but a sentinel lymph node biopsy is generally recommended to verify that the cancer has not spread undetected.
If the lymph nodes come back clear, close surveillance continues. If high-risk features are present (ulcerated tumors thicker than 2 mm, for example), adjuvant therapy may be discussed. Pembrolizumab, a checkpoint inhibitor immunotherapy drug, is approved as adjuvant treatment in this setting to reduce the chance of the cancer returning.
Stage III means melanoma cells have reached the regional lymph nodes. Treatment typically involves surgically removing the affected nodes (lymph node dissection) alongside the primary tumor. After surgery, systemic therapy is strongly recommended to address any remaining microscopic disease.
Two main systemic approaches are used at this stage.
Immunotherapy with checkpoint inhibitors works by releasing the brakes on the immune system so it can find and destroy cancer cells. The most commonly used agents are pembrolizumab (Keytruda) and nivolumab (Opdivo), both of which block a protein called PD-1 that cancer cells exploit to hide from immune surveillance. These drugs are given by intravenous infusion, typically every three to six weeks for a year or more.
Targeted therapy is an option for tumors that carry a BRAF V600 mutation, which occurs in roughly 40 to 50 percent of melanomas. The standard combination is dabrafenib plus trametinib. Dabrafenib blocks the mutated BRAF protein that drives tumor growth; trametinib blocks a downstream signal called MEK. Together they can produce rapid tumor shrinkage. Because resistance can develop, targeted therapy is often used alongside or as an alternative to immunotherapy depending on the clinical situation and patient preferences.
Molecular testing to check for BRAF mutations is done routinely after a melanoma diagnosis, and results guide which systemic treatment is most appropriate.
When melanoma has spread to distant sites, including the lungs, liver, brain, or other organs, the disease is classified as Stage IV. This stage once carried a very poor prognosis, but treatment advances over the past fifteen years have dramatically improved outcomes for many patients.
Immunotherapy is typically the first treatment discussed for Stage IV melanoma. In addition to single-agent pembrolizumab or nivolumab, combining nivolumab with ipilimumab (a drug that blocks a different immune checkpoint called CTLA-4) produces higher response rates, though also more side effects. Combination immunotherapy is appropriate for patients who can tolerate the additional toxicity.
For BRAF-mutated Stage IV disease, targeted therapy with dabrafenib and trametinib can be used, particularly when a rapid response is needed (for example, when the disease is progressing quickly). Some patients receive targeted therapy first and move to immunotherapy later.
Brain metastases, which occur in a significant portion of advanced melanoma cases, may be treated with stereotactic radiosurgery (focused radiation), whole-brain radiation, or immunotherapy, sometimes in combination.
Clinical trials remain an important option at every stage, and especially at Stage IV. Trials are investigating novel combinations, new checkpoint targets, and next-generation approaches.
One emerging approach is tumor-infiltrating lymphocyte (TIL) therapy, a form of adoptive cell therapy. Immune cells are extracted directly from the patient's tumor, expanded in a laboratory to large numbers, and then infused back into the patient. The FDA approved the first TIL therapy (lifileucel) for advanced melanoma in 2024, offering a new option for patients who have not responded to prior immunotherapy.
Ongoing research is also evaluating personalized cancer vaccines, antibody-drug conjugates, and new combinations designed to overcome resistance to existing treatments.
Because checkpoint inhibitors release the immune system's natural brakes, they can cause the immune system to attack healthy tissues. These immune-related adverse events (irAEs) can affect nearly any organ and vary widely in severity.
Common effects include fatigue, skin rash or itching, and diarrhea. More serious but less frequent effects include inflammation of the lungs (pneumonitis), liver (hepatitis), thyroid gland, colon, or pituitary gland. In most cases, these side effects are manageable if caught early.
Reporting new or worsening symptoms promptly to your oncology team is critical. Many immune-related side effects are treated with corticosteroids and, if serious, may require pausing or stopping immunotherapy.
Targeted therapy with BRAF and MEK inhibitors carries a different side effect profile, including joint pain, fever, skin thickening or sensitivity, and elevated blood pressure. Fatigue and nausea are also common.
Ongoing surveillance after melanoma treatment serves two purposes: detecting recurrence and catching new primary melanomas early.
The schedule varies by stage and treatment type. After early-stage surgery, most guidelines recommend full-body skin exams every three to twelve months for the first five years, then annually. Higher-stage patients and those on adjuvant therapy are seen more frequently and may need periodic imaging (CT scans, PET scans, or MRI) to check for internal recurrence.
Blood tests, including lactate dehydrogenase (LDH) levels and circulating tumor DNA in some settings, may be monitored over time.
Patients treated with immunotherapy need ongoing thyroid function checks and other labs to catch late-onset hormonal side effects, which can appear months after treatment ends.
A melanoma diagnosis carries real psychological weight. Fear of recurrence is common, and many patients experience anxiety or depression at some point during or after treatment. These responses are normal.
Support resources include oncology social workers, patient navigator programs, and condition-specific organizations that connect patients with others who have been through similar experiences. Talking openly with your care team about emotional health is just as important as addressing physical symptoms.
If anxiety or low mood is interfering with daily life, ask your oncologist for a referral to a mental health professional with experience in oncology.
Between appointments, questions arise. You might wonder whether a new skin change warrants an urgent call to your dermatologist, or want to understand a test result before your next visit. Doctronic.ai lets you connect with a licensed clinician by text or video to get those questions answered quickly, from anywhere. It does not replace your oncology team, but it can help you stay informed and act on concerns without delay.
Staging is based on the Breslow depth of the tumor, whether it is ulcerated, the mitotic rate, and whether cancer cells are found in the sentinel lymph nodes or at distant sites. Your surgical pathology report and any biopsy results from lymph nodes inform the final stage.
Yes, recurrence is possible even after successful early-stage treatment. This is why follow-up skin exams and, for higher-stage patients, periodic imaging are essential. Most recurrences happen within the first two to three years, though late recurrences beyond five years do occur.
It means the tumor carries a mutation in the BRAF gene (most commonly BRAF V600E) that drives uncontrolled cell growth. This mutation can be targeted with specific drugs, dabrafenib and trametinib, that block the abnormal protein. Testing for BRAF mutations is now standard practice after diagnosis.
Immunotherapy is typically the first-line recommendation for most Stage III and Stage IV melanomas. Whether a patient receives single-agent or combination immunotherapy, or starts with targeted therapy instead, depends on BRAF mutation status, how quickly the disease is progressing, the patient's overall health, and individual preferences.
It depends on the stage and treatment type. Wide local excision for early-stage melanoma is a single outpatient procedure with a recovery period of weeks. Adjuvant immunotherapy for Stage II or Stage III disease typically runs for about a year. Stage IV treatment is ongoing and adjusted based on response and tolerability.
Protecting your skin from UV exposure, including wearing broad-spectrum sunscreen, protective clothing, and avoiding tanning beds, reduces the risk of new primary melanomas. Keeping all scheduled follow-up appointments is essential for catching any changes early.
Melanoma treatment has advanced substantially, and early-stage disease has excellent outcomes. Stage III and Stage IV melanoma now have systemic therapies that were not available a generation ago. Knowing your stage, your BRAF mutation status, and which options are on the table gives you the foundation to work effectively with your care team and make confident decisions throughout treatment and follow-up.
What an Anxiety Attack Actually IsAn anxiety attack is a sudden episode of intense anxiety or fear accompanied by physical symptoms including racing heart, shortness of [...]
Read MoreWhy People Look Beyond PrescriptionsDepression is one of the most common mental health conditions in the United States. About 67% of adults who experienced a major depressive [...]
Read MoreDepression Is Not a Linear ProgressionDepression does not progress through a fixed, predictable sequence of stages the way some medical conditions do. The term [...]
Read More
Join 50,000+ readers using Doctronic to understand symptoms, medications,
and next steps.
Add your phone number below to get health updates and exclusive VIP offers.
By providing your phone number, you agree to receive SMS updates from Company. Message and data rates may apply. Reply “STOP” to opt-out anytime. Read our Privacy Policy and Terms of Service for more details.
Save your consults. Talk with licensed doctors and manage your health history.
